This blog was featured on Clinical Trial AI Weekly. For centuries, science fiction writers have toyed with the endless possibilities of artificial intelligence (AI). And now we’re living the future those writers celebrated and also feared. How might AI apply in the realities of our…
An interesting element of every DIA annual meeting is the variety of voices that are brought together from across the drug development ecosphere. From industry to regulatory bodies, academia, and even students, diverse backgrounds and experiences are brought to the table. The cumulative effect is…
Hello from the 2022 DIA Global Annual Meeting. Not surprisingly, decentralized clinical trial approaches has the spotlight here. This includes: Wearables and sensors for remote data collection Mobile screening units Home trial visits Also in the spotlight at the DIA meeting is the rise of…
Our brains and bodies are complex — humans are still a fascinating mystery. For a perfect example, how about the placebo effect? Placebos are at the core of clinical trials, and using study placebos helps establish efficacy. Researchers are still trying to understand how and…
I was asked to give my perspective on placebo-controlled trials. Using a study placebo presents challenges in recruitment and retention, especially because participants tend to hope that joining a study will lead to a positive treatment response. As I have mentioned in quite a few…